Compare TG Therapeutics Inc (TGTX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vale SA — how do they compare? TG Therapeutics Inc trades at $49.61 (market cap $7.64B), while Vale SA trades at $14.44 (market cap $61.97B). The key difference: Vale SA is far larger — about 8.1× TG Therapeutics Inc's market cap, and Vale SA pays a 8.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VALE | |
|---|---|---|
Market Cap | $7.64B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $17.82 |
52-Week Low | $26.94 | $9.71 |
Enterprise Value | $7.84B | $78.22B |
Dividend Yield | — | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
VALE trades at $14.49, down 2.72% with a bearish technical outlook. Recent earnings missed expectations for three consecutive quarters, with Q3 2026 results pending. The company maintains strong cash flow generation ($8.8B operating cash flow in 2025) and a 5.11% net margin, though profitability has declined from 2022 peaks. Analyst consensus is mixed with 38% Buy ratings and a $16.79 price target, representing 16% upside potential.
VALE offers value with reasonable valuations (P/E 28.6, P/B 1.6) and dividend yield, but faces headwinds from rising costs and earnings volatility. The stock's near-term trajectory depends on Q3 earnings delivery and copper segment execution. Key risks include commodity price sensitivity and operational challenges in base metals expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
